tiprankstipranks
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges
PremiumCompany AnnouncementsKymera Therapeutics’ Earnings Call Highlights Progress and Challenges
14d ago
Kymera Therapeutics: Balancing Promising Pipeline Advancements with Clinical Success Uncertainties
Premium
Ratings
Kymera Therapeutics: Balancing Promising Pipeline Advancements with Clinical Success Uncertainties
14d ago
Kymera Therapeutics: Buy Rating Affirmed Amid Promising STAT6 Program Developments and Adjusted Price Target
Premium
Ratings
Kymera Therapeutics: Buy Rating Affirmed Amid Promising STAT6 Program Developments and Adjusted Price Target
15d ago
Is KYMR a Buy, Before Earnings?
PremiumPre-EarningsIs KYMR a Buy, Before Earnings?
25d ago
Kymera Therapeutics Unveils 2025 Strategy and Trials
Premium
Company Announcements
Kymera Therapeutics Unveils 2025 Strategy and Trials
2M ago
Kymera Therapeutics announces corporate goals for 2025
Premium
The Fly
Kymera Therapeutics announces corporate goals for 2025
2M ago
Kymera Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
PremiumThe FlyKymera Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
3M ago
Kymera Therapeutics initiated with an Overweight at Stephens
Premium
The Fly
Kymera Therapeutics initiated with an Overweight at Stephens
4M ago
Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
Premium
The Fly
Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100